Every material Form 8-K DBV Technologies S.A. has filed with the SEC since July 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DBV Technologies reported a third-quarter 2026 net loss of $64.5 million, up from $33.2 million a year earlier, as research, sales, and administrative spending rose ahead of a potential U.S. launch. The filing states that substantial doubt exists about the company's ability to continue as a going concern, and that its $165.7 million in cash funds operations only into the third quarter of 2027. Shareholders should note that the company says it will need additional capital, with availability and terms uncertain.
Q3 2026 net loss was $64.5 million versus $33.2 million in Q3 2025; net loss per share was $0.14 versus $0.24.
Cash and cash equivalents were $165.7 million as of September 30, 2026, which the company says funds operations into the third quarter of 2027.
The BLA for the VIASKIN Peanut Patch in children aged 4 through 7 was submitted on September 29, 2026, with Priority Review requested; FDA's filing decision is expected in Q4 2026.
The company refreshed its $150 million ATM program and reports a $50 million gross proceeds sale of ADSs to RA Capital Management.
DBV Technologies said it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its VIASKIN Peanut Patch in children with peanut allergy aged 4 through 7 years, and has requested Priority Review. The application is supported by results from the Phase 3 VITESSE trial, which enrolled 654 children, and the FDA previously granted the patch Breakthrough Therapy Designation. The filing reports a regulatory milestone, not revenue or approval, and the company states the product has not been authorized for sale in any country.
BLA submitted to the FDA for VIASKIN Peanut Patch in children aged 4 through 7 years, announced September 29, 2026
DBV has requested Priority Review; the FDA previously granted Breakthrough Therapy Designation
VITESSE Phase 3 trial enrolled 654 children, randomized 2:1 to active patch or placebo
The company states the product has not been authorized for sale in any country
DBV Technologies reported a second-quarter 2026 net loss of $50.4 million, up from $41.9 million a year earlier, with six-month losses of $98.0 million versus $69.0 million. The company said it now expects to submit its BLA for the VIASKIN Peanut Patch in the third quarter of 2026, and it reported $174.9 million in cash, funding operations into the third quarter of 2027.
Q2 2026 net loss was $50.4 million, up from $41.9 million in Q2 2025; six-month net loss was $98.0 million versus $69.0 million.
Six-month R&D expenses rose to $64.6 million from $55.2 million, and SG&A rose by $20.7 million, as the company prepares for a potential U.S. launch.
Cash and cash equivalents were $174.9 million as of June 30, 2026, funding operations into the third quarter of 2027.
BLA submission for VIASKIN Peanut Patch in children aged 4 through 7 is now anticipated in the third quarter of 2026, after the prior timing of the second quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DBV Technologies S.A. filing is on SEC EDGAR ↗. 8-K briefs of other companies →